Trial Profile
Pharmacodynamics of intravitreal Ranibizumab in previously untreated patients with retinal vein occlusion
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Sep 2015
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Retinal vein occlusion
- Focus Pharmacodynamics
- 15 Sep 2015 New trial record
- 01 Jul 2015 Results published in the American Journal of Ophthalmology.